Articles

Sort by
Previous Page Page 2 of 58 Next Page
  1. Research article

    Evaluation of dosing strategy for pembrolizumab for oncology indications

    Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pe...

    Tomoko Freshwater, Anna Kondic, Malidi Ahamadi, Claire H. Li, Rik de Greef, Dinesh de Alwis and Julie A. Stone

    Journal for ImmunoTherapy of Cancer 2017 5:43

    Published on: 16 May 2017

  2. Research article

    A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...

    Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas

    Journal for ImmunoTherapy of Cancer 2017 5:42

    Published on: 16 May 2017

  3. Review

    Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

    As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic...

    Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton and Lisa H. Butterfield

    Journal for ImmunoTherapy of Cancer 2017 5:44

    Published on: 16 May 2017

  4. Case report

    Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer

    Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence ...

    James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra and Colleen Veloski

    Journal for ImmunoTherapy of Cancer 2017 5:40

    Published on: 16 May 2017

  5. Commentary

    Tissue-resident lymphocytes: sentinel of the transformed tissue

    Tumor cells can be detected and cleared by lymphocytes in a process termed cancer immunosurveillance. However, the contributing cell types had not been fully characterized. Using oncogene-induced murine models...

    Saïda Dadi and Ming O. Li

    Journal for ImmunoTherapy of Cancer 2017 5:41

    Published on: 16 May 2017

  6. Research article

    Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

    Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor ...

    Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma…

    Journal for ImmunoTherapy of Cancer 2017 5:35

    Published on: 18 April 2017

  7. Research article

    Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...

    Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy

    Journal for ImmunoTherapy of Cancer 2017 5:33

    Published on: 18 April 2017

  8. Meeting report

    The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting

    As healthcare costs continue to rise, there has been great interest in understanding and defining the value of current therapeutic strategies for the treatment of cancer. Cancer immunotherapy has emerged as a ...

    Howard L. Kaufman, Michael B. Atkins, Adam P. Dicker, Heather S. Jim, Louis P. Garrison, Roy S. Herbst, William T. McGivney, Steven Silverstein, Jon M. Wigginton and Peter P. Yu

    Journal for ImmunoTherapy of Cancer 2017 5:38

    Published on: 18 April 2017

  9. Research article

    Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death

    We have been developing a non-thermal, drug-free tumor therapy called Nano-Pulse Stimulation (NPS) that delivers ultrashort electric pulses to tumor cells which eliminates the tumor and inhibits secondary tumo...

    Richard Nuccitelli, Amanda McDaniel, Snjezana Anand, John Cha, Zachary Mallon, Jon Casey Berridge and Darrin Uecker

    Journal for ImmunoTherapy of Cancer 2017 5:32

    Published on: 18 April 2017

  10. Research article

    A systems biology approach to investigating the influence of exercise and fitness on the composition of leukocytes in peripheral blood

    Exercise immunology has become a growing field in the past 20 years, with an emphasis on understanding how different forms of exercise affect immune function. Mechanistic studies are beginning to shed light on...

    Michael P. Gustafson, Ara Celi DiCostanzo, Courtney M. Wheatley, Chul-Ho Kim, Svetlana Bornschlegl, Dennis A. Gastineau, Bruce D. Johnson and Allan B. Dietz

    Journal for ImmunoTherapy of Cancer 2017 5:30

    Published on: 18 April 2017

  11. Research article

    Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

    Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogene...

    Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez and Constantin N. Baxevanis

    Journal for ImmunoTherapy of Cancer 2017 5:39

    Published on: 18 April 2017

    The Erratum to this article has been published in Journal for ImmunoTherapy of Cancer 2017 5:48

  12. Case report

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Prostate cancer is one of the most common cancers in men and the fourth leading cause of cancer mortality worldwide. Although major progress has been achieved in the last years for patients with metastatic cas...

    Luc Cabel, Elika Loir, Gwenaelle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albiges, Giulia Baciarello, Yohann Loriot and Karim Fizazi

    Journal for ImmunoTherapy of Cancer 2017 5:31

    Published on: 18 April 2017

  13. Review

    Systematic evaluation of immune regulation and modulation

    Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in ...

    David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri and Barbara Seliger

    Journal for ImmunoTherapy of Cancer 2017 5:21

    Published on: 21 March 2017

  14. Meeting report

    Immunotherapy biomarkers 2016: overcoming the barriers

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...

    James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…

    Journal for ImmunoTherapy of Cancer 2017 5:29

    Published on: 21 March 2017

  15. Research article

    Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer

    T cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined. Here we report results ...

    Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

    Journal for ImmunoTherapy of Cancer 2017 5:22

    Published on: 21 March 2017

  16. Research article

    Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy

    Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing imp...

    Ryan Urak, Miriam Walter, Laura Lim, ChingLam W. Wong, Lihua E. Budde, Sandra Thomas, Stephen J. Forman and Xiuli Wang

    Journal for ImmunoTherapy of Cancer 2017 5:26

    Published on: 21 March 2017

  17. Research article

    Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...

    James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm

    Journal for ImmunoTherapy of Cancer 2017 5:25

    Published on: 21 March 2017

  18. Short report

    Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

    Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor types. Unresectable or metastatic...

    Evan J. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Megan Schollenberger, William H. Sharfman and Janis M. Taube

    Journal for ImmunoTherapy of Cancer 2017 5:23

    Published on: 21 March 2017

  19. Case report

    Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)

    CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) was the first immune checkpoint receptor clinically targeted for use in cancer treatment. It is expressed exclusively on T-cells where its primary role is t...

    Jeanelle King, Javier de la Cruz and Jose Lutzky

    Journal for ImmunoTherapy of Cancer 2017 5:19

    Published on: 21 March 2017

  20. Meeting abstracts

    Abstracts from the 4th ImmunoTherapy of Cancer Conference

    J. Ženka, V. Caisová, O. Uher, P. Nedbalová, K. Kvardová, K. Masáková, G. Krejčová, L. Paďouková, I. Jochmanová, K. I. Wolf, J. Chmelař, J. Kopecký, L. Loumagne, J. Mestadier, S. D’agostino, A. Rohaut…

    Journal for ImmunoTherapy of Cancer 2017 5(Suppl 1):12

    Published on: 20 March 2017

    This article is part of a Supplement: Volume 5 Supplement 1

Previous Page Page 2 of 58 Next Page
JITC logo

Advertisement